Oncopeptides AB (ST:ONCO) — Market Cap & Net Worth
Market Cap & Net Worth: Oncopeptides AB (ONCO)
Oncopeptides AB (ST:ONCO) has a market capitalization of $65.87 Million (Skr612.12 Million) as of June 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #20896 globally and #375 in its home market, demonstrating a -6.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncopeptides AB's stock price Skr1.61 by its total outstanding shares 381148118 (381.15 Million). Review total liabilities of Oncopeptides AB to assess the company's total debt and financial obligations.
Oncopeptides AB Market Cap History: 2017 to 2026
Oncopeptides AB's market capitalization history from 2017 to 2026. Data shows change from $3.28 Billion to $65.87 Million (-29.73% CAGR).
Oncopeptides AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncopeptides AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.77x
Oncopeptides AB's market cap is 2.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $6.96 Billion | $19.36 Million | -$1.59 Billion | 359.63x | N/A |
| 2021 | $344.55 Million | $118.30 Million | -$1.43 Billion | 2.91x | N/A |
| 2022 | $498.36 Million | $8.36 Million | -$337.95 Million | 59.65x | N/A |
| 2023 | $314.20 Million | $35.22 Million | -$249.11 Million | 8.92x | N/A |
| 2024 | $63.82 Million | $31.65 Million | -$284.61 Million | 2.02x | N/A |
| 2025 | $197.09 Million | $71.12 Million | -$249.59 Million | 2.77x | N/A |
Competitor Companies of ONCO by Market Capitalization
Companies near Oncopeptides AB in the global market cap rankings as of June 18, 2026.
Key companies related to Oncopeptides AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Oncopeptides AB Historical Marketcap From 2017 to 2026
Between 2017 and today, Oncopeptides AB's market cap moved from $3.28 Billion to $ 65.87 Million, with a yearly change of -29.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr65.87 Million | -66.58% |
| 2025 | Skr197.09 Million | +208.80% |
| 2024 | Skr63.82 Million | -79.69% |
| 2023 | Skr314.20 Million | -36.95% |
| 2022 | Skr498.36 Million | +44.64% |
| 2021 | Skr344.55 Million | -95.05% |
| 2020 | Skr6.96 Billion | +33.73% |
| 2019 | Skr5.21 Billion | -3.42% |
| 2018 | Skr5.39 Billion | +64.25% |
| 2017 | Skr3.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Oncopeptides AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $65.87 Million USD |
| MoneyControl | $65.87 Million USD |
| MarketWatch | $65.87 Million USD |
| marketcap.company | $65.87 Million USD |
| Reuters | $65.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more